UNSPSC 51433302: Flavodilol

This classification denotes an antihypertensive agent with the molecular formula C21H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, M8FR1KL85J chemically known as 4h-1-benzopyran-4-one, 7-(2-hydroxy-3-(propylamino)propoxy)-2-phenyl-, (+/-)- but generally known as flavodilol, which bears US NIH Compound Identifier 54410. European Medicines Agency schedules Flavodilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07634MIG.

UNSPSC 51433302 Flavodilol is a Commodity code representing pharmaceutical active ingredients and finished medications that state and local governments procure for emergency medical services, public health programs, and institutional healthcare systems. Recent state and local solicitations under this code show purchasing of advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products distributed across fire rescue services, state health agencies, and cooperative purchasing networks. The scope encompasses both branded and generic formulations supplied through authorized wholesale channels, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) standards, and expiration-date guarantees. City purchasing departments, state health and human services commissions, and multistate cooperative purchasing alliances are the primary issuing bodies, with fire rescue services and institutional healthcare as end-users.

Activity appears concentrated in the South and Upper Midwest, with recent opportunities from Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) in early April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling exploration of alternative procurement channels outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, serving multiple state and local jurisdictions across Minnesota and Oregon through three authorized wholesalers. Vendors must maintain comprehensive insurance, comply with pricing transparency and EDI requirements, and accept performance penalties for reporting or onboarding failures.